Overview

Atacicept in Multiple Glomerular Diseases

Status:
RECRUITING

Trial end date:
2027-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to evaluate the safety and tolerability of atacicept in adult and adolescent participants and to measure the effect in reducing proteinuria and preserving renal function.

Phase:

PHASE2

Details

Lead Sponsor:

Vera Therapeutics, Inc.

Treatments:

TACI receptor-IgG Fc fragment fusion protein